Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400279 | 0.94 | PPARG (0.43) | NOTUMMMP13POLBTP53MAPT | |
| SCHEMBL2397972 | 0.90 | NOTUM (0.51) | HDAC1NOTUMCNR2CNR1 | |
| SCHEMBL2213496 | 0.89 | P2RX7 (0.42) | MMP13 | |
| SCHEMBL2214252 | 0.89 | LMNA (0.45) | NOTUMCNR2CNR1MMP13POLB | |
| SCHEMBL2215833 | 0.87 | NOTUM (0.40) | PTGER4NOTUMPOLBTP53MAPT | |
| SCHEMBL2399044 | 0.86 | NPC1 (0.46) | NOTUMMMP13IDO1POLBTP53 | |
| SCHEMBL2397367 | 0.85 | NOTUM (0.42) | HDAC1NOTUMCNR2CNR1IDO1 | |
| SCHEMBL2212108 | 0.85 | CNR1 (0.43) | NOTUMCNR1POLBTP53MAPT | |
| SCHEMBL2220555 | 0.83 | KLKB1 (0.46) | PTGER4NOTUMMMP13POLBTP53 | |
| SCHEMBL2214186 | 0.83 | SMN1; SMN2 (0.46) | HDAC1PTGER4NOTUMCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | claimed |
| EP-2341776-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2010033626-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-03-25 | — | — | WO | claimed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | HDAC3 1811/4885HDAC1 2458/4885HDAC2 3045/4885 |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | HDAC3 651/4885HDAC1 1369/4885HDAC2 2046/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | HDAC3 1811/4885HDAC1 2458/4885HDAC2 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.